

June 4, 2026

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received an order from the Deputy Commissioner of State Tax (Appeal), being passed under section 107 of the Maharashtra Goods and Services Act, 2017 for financial year 2018-19 on June 3, 2026.

The captioned order is a development in the appeal filed by the Company on 29th June 2020 against the order issued by Assistant Commissioner of State Tax Investigation, which had been intimated to the Stock Exchanges vide intimation dated August 14, 2023.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking you,

For AstraZeneca Pharma India Limited

Tanya Sanish

Company Secretary & Compliance Officer

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the opposing party	Deputy Commissioner of State Tax (Appeal)
2.	Brief details of dispute/litigation	Company has received an appeal order for the financial year 2018-19, wherein certain adjustments initially made by the Assistant Commissioner of State Tax Investigation relating to supplies made by the Company under Patient Access Program, have been upheld by the Deputy Commissioner of State Tax (Appeal).
3.	Court/tribunal/agency where the litigation is filed	The order was passed by the Deputy Commissioner of State Tax (Appeal). The matter will be challenged before the GST Appellate Tribunal (GSTAT) by filing an appeal.
4.	Expected financial implications, if any, due to compensation, penalty etc.	Matter will be suitably challenged in due course. The expected overall financial implication cannot be determined at this stage.
5.	Quantum of claims, if any	Rs. 9.24 crores (approx.) excluding interest and penalty.